A test kit can look identical to another product on the shelf, yet have a very different intended use, regulatory status and result pathway. For Australian buyers, understanding TGA test requirements is the practical way to avoid ordering a kit that cannot be used in your clinic, aged care service, workplace or home setting.
This matters most when buying rapid antigen tests, combination COVID-19 and influenza tests, drug screening products, pregnancy tests and other in vitro diagnostic devices. The right product is not simply the lowest-priced option. It needs to be supplied for the intended Australian use, correctly labelled, within expiry and supported by clear instructions.
What the TGA regulates in diagnostic tests
The Therapeutic Goods Administration, or TGA, regulates therapeutic goods supplied in Australia. Most diagnostic test kits fall within the category of in vitro diagnostic medical devices, often shortened to IVDs. These are devices that examine a specimen taken from the human body, such as a nasal swab, saliva sample, urine or blood sample, to provide information about health.
Before an IVD can generally be supplied in Australia, it must be included in the Australian Register of Therapeutic Goods, known as the ARTG. The Australian sponsor is responsible for making sure the device meets applicable regulatory requirements and remains appropriately supplied in the market.
Buyers often use the phrase “TGA-approved test”. It is common shorthand, but ARTG inclusion is the more precise check. The key procurement question is whether the specific test, model and intended use are included on the ARTG and supplied by an authorised Australian sponsor.
That distinction is worth making. A manufacturer may sell a very similar product overseas, but that does not automatically mean the same product can be supplied or used in Australia for the same purpose.
TGA test requirements depend on intended use
The label and instructions for use are not just paperwork. They define what the test is designed to do, who can use it, which samples it accepts and how results should be interpreted.
A COVID-19 rapid antigen test authorised for self-testing is designed for use by lay users in a home or non-clinical environment, provided the instructions are followed. A point-of-care test is intended for use in a healthcare setting by trained staff or under appropriate clinical processes. A laboratory test may require specialised equipment and qualified personnel.
These categories are not interchangeable. A clinic should not assume a self-test is suitable for an occupational screening program, nor should a household buyer purchase a professional-use device expecting it to be simple to administer at home. Select the test based on the actual setting, user and workflow.
For combination respiratory tests, check exactly what the kit detects. Some products detect COVID-19 and influenza A/B. Others may include respiratory syncytial virus, or RSV. The product claim should clearly state the organisms covered, the sample type accepted and the testing window or symptom criteria where relevant.
What buyers should check before ordering test kits
For practices, aged care providers and procurement teams, a consistent buying checklist prevents avoidable compliance issues. Before adding a test kit to a regular order, confirm the following details with the product listing, label and supplied documentation:
- The device is listed on the ARTG for the intended Australian use.
- The ARTG entry, brand name, model and supplied product match.
- The test is suitable for self-testing, point-of-care use or professional use, as required.
- The instructions for use are provided in English and are available to the end user.
- Storage conditions can be maintained from delivery through to use.
- The expiry date leaves enough usable shelf life for your expected stock turnover.
- The test detects the condition or combination of conditions you actually need to screen for.
Storage, transport and expiry are part of compliance
Diagnostic kits are sensitive products. Heat, moisture, freezing temperatures and damaged packaging can affect their performance. The storage range printed on the pack or in the instructions must be followed, including during periods when stock is held in a storeroom, vehicle or treatment area.
This is especially relevant for Melbourne buyers collecting stock locally or receiving deliveries during hot weather. Do not leave test kits in a ute, unattended loading area or direct sunlight for extended periods. Once stock arrives, inspect cartons for damage, move products into suitable storage and rotate inventory so the earliest expiry is used first.
A test past its expiry date should not be used. The same applies where a kit is incomplete, the sealed pouch is damaged, reagents have leaked or the device has been stored outside its specified conditions. Saving a small amount on a discounted short-dated product is rarely worthwhile if staff cannot use it confidently when demand increases.
Performance claims need context
Sensitivity and specificity figures can be useful, but they are not the whole buying decision. Test performance is influenced by the sample collection method, timing of infection, user technique and whether instructions are followed precisely.
A rapid antigen test is designed to support a particular testing purpose and should be interpreted according to its instructions. A negative result does not always rule out infection, particularly where symptoms are present or exposure is recent. A positive, negative or invalid result may trigger different workplace, clinical or public health actions depending on current advice and the setting.
For procurement purposes, avoid comparing test kits solely on a headline accuracy percentage. Consider whether the kit suits your user group, whether staff can follow the process reliably, whether the result time fits the workflow and whether replacement stock can be obtained quickly. A reliable supply line matters when a practice needs tests alongside gloves, masks, disinfectant and other high-turnover infection-control essentials.
Avoid common purchasing mistakes
The most common mistake is buying a test based on packaging or online claims without checking its Australian supply status and intended purpose. Products promoted for overseas markets may have different directions, different regulatory arrangements or no appropriate Australian pathway for the use you need.
Another issue is confusing screening with diagnosis. A rapid test result can be valuable for immediate decision-making, but it may not replace clinical assessment or confirmatory testing where that is indicated. Clinics should have a clear internal process for documenting results, handling invalid tests, advising patients and escalating concerns to an appropriate clinician.
It is also sensible to maintain records of supplier invoices, batch details and expiry dates, particularly for larger orders or institutional use. Good records make stock rotation easier and help identify affected products if a supplier issues a safety notice or recall.
Choosing a dependable test supplier
A dependable supplier makes it easier to meet day-to-day purchasing requirements. Look for clear Australian product information, visible expiry and storage details, stock availability that reflects actual demand, and a team that can help distinguish between product types when needed.
For high-use items, buying from one supplier can reduce administration and prevent missed replenishment orders. ToBe HealthCare supports clinics, aged care providers, resellers and home users with diagnostic products alongside PPE, hygiene consumables and broader medical supplies, helping buyers keep routine essentials moving without unnecessary delays.
Regulatory confidence should sit alongside practical purchasing decisions: buy the test that matches its stated use, protect its storage conditions and order quantities your team can use in time. That approach keeps testing simple, reduces avoidable waste and gives staff and patients greater confidence in every result.
